Ilaria Lucca

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


81 publications

In press | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2009 | 2008 |
In press
 
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine.
Afferi L., Spahn M., Hayoz S., Strebel R.T., Rothschild S.I., Seifert H., Özdemir B.C., Kiss B., Maletzki P., Engeler D. et al. BJU international. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_29095525B6AB]
2024
 
Hyperthermic Intravesical Chemotherapy (HIVEC) Using Epirubicin in an Optimized Setting in Patients with NMIBC Recurrence after Failed BCG Therapy.
Blanc J., Ruggiero J., Lucca I., Arnold N., Kiss B., Roth B., 2024/04/02. Cancers, 16 (7). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F1C88253D231]
Respiratory Complications after Cystectomy with Urinary Diversion: Avoidable Complications or Ineluctable Destiny?
Martinez Carrique S., Crettenand F., Stritt K., Bohner P., Grilo N., Rodrigues-Dias S., Roth B., Lucca I., 2024/03/10. Journal of clinical medicine, 13 (6). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_518002D428C9]
 
Impact of Enhanced Recovery after Surgery<sup>®</sup> Protocol Compliance on Length of Stay, Bowel Recovery and Complications after Radical Cystectomy.
Grilo N., Crettenand F., Bohner P., Rodrigues Dias S.C., Cerantola Y., Lucca I., 2024/01/25. Diagnostics, 14 (3). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D830B5AFB18F]
2023
 
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.
Derré L., Lucca I., Cesson V., Bohner P., Crettenand F., Rodrigues-Dias S.C., Dartiguenave F., Masnada A., Teixeira-Pereira C., Benmerzoug S. et al., 2023/12/14. Journal for immunotherapy of cancer, 11 (12) pp. e008020. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_05D137E31CE9]
 
Cancer de la vessie : un suivi personnalisé pour une prise en charge efficiente [Bladder cancer : a comprehensive follow-up for an efficient and personalized care]
Bohner P., Pal M., Crettenand F., Roth B., Lucca I., 2023/11/29. Revue medicale suisse, 19 (852) pp. 2250-2253. Peer-reviewed.
[URN][Pmid][serval:BIB_E74D1ABF6507]
 
Cystectomie radicale chez les patients gériatriques. Outils de dépistage des complications postopératoires [Radical cystectomy in the geriatric population. Tools for screening postoperative complications]
Reale S., Bohner P., Crettenand F., Roth B., Lucca I., 2023/11/29. Revue medicale suisse, 19 (852) pp. 2247-2249. Peer-reviewed.
[URN][Pmid][serval:BIB_704D74C8C0BA]
 
Un registre des cystectomies de la Société suisse d’urologie pour une meilleure qualité chirurgicale [A Swiss Urological Society register of cystectomies to improve surgical quality]
Pal M., Bohner P., Crettenand F., Roth B., Lucca I., 2023/11/29. Revue medicale suisse, 19 (852) pp. 2254-2256. Peer-reviewed.
[URN][Pmid][serval:BIB_4B8743AE4A68]
Do Swiss urologists and Swiss internists screen themselves and their relatives for prostate cancer? A questionnaire study.
Scherer T.P., Saba K., Wettstein M.S., Lucca I., Mortezavi A., Waisbrod S., Aujesky D., Capaul R., Strebel R.T., 2023/09/14. Swiss medical weekly, 153 p. 40115. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7D39FBEBAFAC]
Association Between Antibiotic Prophylaxis Before Cystectomy or Stent Removal and Infection Complications: A Systematic Review.
Antonelli L., Sebro K., Lahmar A., Black P.C., Ghodoussipour S., Hamilton-Reeves J.M., Shah J., Bente Thoft J., Lerner S.P., Llorente C. et al., 2023/07. European urology focus, 9 (4) pp. 631-636. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CF5E10DCC184]
2022
Is EDSS Enough to Predict Risk of Upper Urinary Tract Damage in Patients with Multiple Sclerosis?
Stritt K., Lucca I., Roth B., Grilo N., 2022/11/22. Biomedicines, 10 (12) p. 3001. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9CBFD3BA5D1C]
Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile.
Lucca I., Derré L., Cesson V., Bohner P., Crettenand F., Rodrigues-Dias S., Dartiguenave F., Masnada A., Texeira-Pereira C., Benmerzoug S. et al., 2022/11. European urology open science, 45 pp. 55-58. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6BF6056A37F5]
ERAS® protocol improves survival after radical cystectomy: A single-center cohort study.
Crettenand F., M'Baya O., Grilo N., Valerio M., Dartiguenave F., Cerantola Y., Roth B., Rouvé J.D., Blanc C., Lucca I., 2022/09/02. Medicine, 101 (35) pp. e30258. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DCB34BAF3D6A]
Syndrome du casse-noisette : une cause d’hématurie inexpliquée [Nutcracker syndrome: a cause of unexplained hematuria]
Rousseau S., Lucca I., Selby K., 2022/08/24. Revue medicale suisse, 18 (792) pp. 1566-1569. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_516D309A6506]
 
Corrigendum to < Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer>, urologic oncology: Seminars and original investigations volume 35, issue 6, June 2017, pages 356-362.
Soria F., Lucca I., Moschini M., Mathieu R., Rouprêt M., Karakiewicz P.I., Briganti A., Rink M., Gust K.M., Hassler M.R. et al., 2022/08. Urologic oncology, 40 (8) p. 387. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_64AACAAB00E4]
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
Nguyen S., Chevalier M.F., Benmerzoug S., Cesson V., Schneider A.K., Rodrigues-Dias S.C., Dartiguenave F., Lucca I., Jichlinski P., Roth B. et al., 2022/08. Journal for immunotherapy of cancer, 10 (8) pp. e004880. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_430EBCEC5757]
 
A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
Rentsch C.A., Thalmann G.N., Lucca I., Kwiatkowski M., Wirth G.J., Strebel R.T., Engeler D., Pedrazzini A., Hüttenbrink C., Schultze-Seemann W. et al., 2022/04. European urology oncology, 5 (2) pp. 195-202. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6DE024A4164B]
2021
Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.
Benmerzoug S., Chevalier M.F., Villier L., Nguyen S., Cesson V., Schneider A.K., Dartiguenave F., Rodrigues-Dias S.C., Lucca I., Jichlinski P. et al., 2021/12. European urology open science, 34 pp. 79-82. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_00BEA50EB5F4]
Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study.
Rakauskas A., Tawadros T., Lucca I., Herrera F., Bourhis J., Burruni R., Gomes M.N., Codeluppi C., Jolliet L., La Rosa S. et al., 2021/07. Investigative and clinical urology, 62 (4) pp. 416-422. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_11DA8B398364]
 
The utility of in-bore multiparametric magnetic resonance-guided biopsy in men with negative multiparametric magnetic resonance-ultrasound software-based fusion targeted biopsy.
Perrin A., Venderink W., Patak M.A., Möckel C., Fehr J.L., Jichlinski P., Porcellini B., Lucca I., Futterer J., Valerio M., 2021/05. Urologic oncology, 39 (5) pp. 297.e9-297.e16. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_75768B5492B4]
2020
 
The utility of intraoperative contrast-enhanced ultrasound in detecting residual disease after focal HIFU for localized prostate cancer.
Bacchetta F., Martins M., Regusci S., Jichlinski P., Meuwly J.Y., Lucca I., Valerio M., 2020/11. Urologic oncology, 38 (11) pp. 846.e1-846.e7. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_913CBD0A1EF2]
 
Intramuscular Immunization Induces Antigen-specific Antibodies in Urine.
Derré L., Lucca I., Cesson V., Valerio M., Cerantola Y., Burruni R., Fritschi U., Gharbi D., Bobst M., Legris A.S. et al., 2020/03/15. European urology focus, 6 (2) pp. 280-283. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_278D1CCE5A4E]
 
ERAS for Major Urological Procedures: Evidence Synthesis and Recommendations
Crettenand François, Martel Paul, Lucca Ilaria, Daneshmand Siamak, Cerantola Yannick, 2020. pp. 421-431 dans Enhanced Recovery After Surgery, Springer International Publishing.
[DOI][serval:BIB_A34149570B44]
2019
Prise en charge de cancers urologiques chez la population âgée : quels enjeux ? [Management of urologic cancers in elderly people : which implications ?]
Schaer S., Valerio M., Jichlinski P., Lucca I., 2019/11/27. Revue medicale suisse, 15 (673) pp. 2195-2197. Peer-reviewed.
[DOI][Pmid][serval:BIB_EAE3635D7B71]
 
Urinary expression of genes involved in DNA methylation and histone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria.
Lucca I., Hofbauer S.L., Haitel A., Susani M., Shariat S.F., Klatte T., De Martino M., 2019/07. Oncology letters, 18 (1) pp. 57-62. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_652574787FA8]
Double Positive CD4<sup>+</sup>CD8<sup>+</sup> T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization.
Bohner P., Chevalier M.F., Cesson V., Rodrigues-Dias S.C., Dartiguenave F., Burruni R., Tawadros T., Valerio M., Lucca I., Nardelli-Haefliger D. et al., 2019. Frontiers in immunology, 10 p. 622. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4BC4F69D1158]
2018
 
A urinary microRNA (miR) signature for diagnosis of bladder cancer.
Hofbauer S.L., de Martino M., Lucca I., Haitel A., Susani M., Shariat S.F., Klatte T., 2018/12. Urologic oncology, 36 (12) pp. 531.e1-531.e8. Peer-reviewed.
[DOI][Pmid][serval:BIB_3BE8406F4AC8]
 
Chirurgie ambulatoire en urologie : il est temps d’en parler [Ambulatory surgery in urology]
Haverdings H., Vola F., Altwegg G., Chollet M., Jichlinski P., Lucca I., 2018/11/28. Revue medicale suisse, 14 (629) pp. 2164-2166. Peer-reviewed.
[Pmid][serval:BIB_F7C47D4B3B59]
 
Réhabilitation améliorée après chirurgie urologique majeure : quel rôle pour le médecin généraliste ? [Improved rehabilitation after major urological surgery : what role for the general practitioner ?]
Martel P., Crettenand F., M'baya O., Cerantola Y., Jichlinski P., Lucca I., 2018/11/28. Revue medicale suisse, 14 (629) pp. 2150-2153. Peer-reviewed.
[Pmid][serval:BIB_93D2E6D6BCC7]
 
Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy.
Chevalier M.F., Schneider A.K., Cesson V., Dartiguenave F., Lucca I., Jichlinski P., Nardelli-Haefliger D., Derré L., 2018/11. European urology, 74 (5) pp. 540-544. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_09E73A101B01]
2017
 
Ablation du cancer primaire dans les néoplasies urologiques oligométastatiques : évidence ou vœux pieux ? [Local treatment in oligometastatic urological malignancies : evidence of wishful thinking ?]
Valerio M., Cerantola Y., Lucca I., Berthold D., Jichlinski P., 2017/11/29. Revue medicale suisse, 13 (585) pp. 2083-2086. Peer-reviewed.
[Pmid][serval:BIB_3B730D56DD60]
Immunothérapie : une révolution dans la prise en charge du cancer de la vessie ? [Immunotherapy : a revolution in the management of urothelial bladder cancer ?]
Adam S.M., Derré L., Jichlinski P., Lucca I., 2017/11/29. Revue medicale suisse, 13 (585) pp. 2074-2078. Peer-reviewed.
[URN][Pmid][serval:BIB_2CC8F9CAC7B2]
 
Carcinome urothélial de la vessie et des voies urinaires hautes
Julita Loïc, Jichlinski Patrice, Lucca Ilaria, 2017/08/30. Forum Médical Suisse ‒ Swiss Medical Forum, 17 (35). Peer-reviewed.
[DOI][serval:BIB_F4EE47AC538E]
 
Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer.
Soria F., Lucca I., Moschini M., Mathieu R., Rouprêt M., Karakiewicz P.I., Briganti A., Rink M., Gust K.M., Hassler M.R. et al., 2017/06. Urologic oncology, 35 (6) pp. 356-362. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5DAC791A3625]
 
Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L., Cesson V., Lucca I., Cerantola Y., Valerio M., Fritschi U., Vlamopoulos Y., Burruni R., Legris A.S., Dartiguenave F. et al., 2017/02/01. Clinical cancer research, 23 (3) pp. 717-725. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7E871163C3ED]
 
Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study.
Mathieu R., Lucca I., Vartolomei M.D., Mbeutcha A., Klatte T., Seitz C., Karakiewicz P.I., Fajkovic H., Sun M., Lotan Y. et al., 2017/02. BJU international, 119 (2) pp. 234-238. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_35622816445B]
Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy.
Vartolomei M.D., Mathieu R., Margulis V., Karam J.A., Rouprêt M., Lucca I., Mbeutcha A., Seitz C., Karakiewicz P.I., Fajkovic H. et al., 2017/01. World journal of urology, 35 (1) pp. 121-130. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_24DDB6EC6BD8]
2016
 
Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer.
Mbeutcha A., Shariat S.F., Rieken M., Rink M., Xylinas E., Seitz C., Lucca I., Mathieu R., Rouprêt M., Briganti A. et al., 2016/11. Urologic oncology, 34 (11) pp. 483.e17-483.e24. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5833EAC86D3D]
 
Association of human telomerase reverse transcriptase gene polymorphisms, serum levels, and telomere length with renal cell carcinoma risk and pathology.
de Martino M., Taus C., Lucca I., Hofbauer S.L., Haitel A., Shariat S.F., Klatte T., 2016/10. Molecular carcinogenesis, 55 (10) pp. 1458-1466. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B4A779A0899A]
 
Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Fajkovic H., Shariat S.F., Klatte T., Vartolomei M.D., Lucca I., Mbeutcha A., Rouprêt M., Briganti A., Karakiewicz P.I., Margulis V. et al., 2016/10. World journal of urology, 34 (10) pp. 1411-1419. Peer-reviewed.
[DOI][Pmid][serval:BIB_999DE1F51220]
 
Development of a Preoperative Nomogram Incorporating Biomarkers of Systemic Inflammatory Response to Predict Nonorgan-confined Urothelial Carcinoma of the Bladder at Radical Cystectomy.
Lucca I., Hofbauer S.L., Leitner C.V., de Martino M., Özsoy M., Susani M., Shariat S.F., Klatte T., 2016/09. Urology, 95 pp. 132-138. Peer-reviewed.
[DOI][Pmid][serval:BIB_4F30218C63DB]
 
Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent.
Mbeutcha A., Lucca I., Margulis V., Karam J.A., Wood C.G., de Martino M., Mathieu R., Haitel A., Xylinas E., Kluth L. et al., 2016/08. World journal of urology, 34 (8) pp. 1155-1161. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A3ADE8ED294E]
 
The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder.
Mathieu R., Lucca I., Rouprêt M., Briganti A., Shariat S.F., 2016/08. Nature reviews. Urology, 13 (8) pp. 471-479. Peer-reviewed.
[DOI][Pmid][serval:BIB_3BBD34AEAF12]
 
Dynamic Prognostication Using Conditional Recurrence and Progression Estimates for Patients with Nonmuscle Invasive Bladder Cancer.
Leitner C.V., Ederer I.A., de Martino M., Hofbauer S.L., Lucca I., Mbeutcha A., Mathieu R., Haitel A., Susani M., Shariat S.F. et al., 2016/07. The Journal of urology, 196 (1) pp. 46-51. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0C28BCC003D6]
 
Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
Lucca I., Shariat S.F., 2016/07. European urology, 70 (1) pp. 205-206. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B866896273E0]
 
Serum Adiponectin Predicts Cancer-specific Survival of Patients with Renal Cell Carcinoma.
de Martino M., Leitner C.V., Hofbauer S.L., Lucca I., Haitel A., Shariat S.F., Klatte T., 2016/06. European urology focus, 2 (2) pp. 197-203. Peer-reviewed.
[DOI][Pmid][serval:BIB_79057EEDD1A2]
 
Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal Ureter.
Seisen T., Nison L., Remzi M., Klatte T., Mathieu R., Lucca I., Bozzini G., Capitanio U., Novara G., Cussenot O. et al., 2016/05. The Journal of urology, 195 (5) pp. 1354-1361. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B171FA090583]
 
Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy.
Fajkovic H., Mathieu R., Lucca I., Hiess M., Hübner N., Al Hussein Al Awamlh B., Lee R., Briganti A., Karakiewicz P., Lotan Y. et al., 2016/05. Urologic oncology, 34 (5) pp. 233.e1-6. Peer-reviewed.
[DOI][Pmid][serval:BIB_B6DDD7225AF7]
 
The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis.
Lucca I., Jichlinski P., Shariat S.F., Rouprêt M., Rieken M., Kluth L.A., Rink M., Mathieu R., Mbeutcha A., Maj-Hes A. et al., 2016/04. European urology focus, 2 (1) pp. 79-85. Peer-reviewed.
[DOI][Pmid][serval:BIB_5B2803795184]
 
Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer.
Mbeutcha A., Lucca I., Mathieu R., Lotan Y., Shariat S.F., 2016. Urologic Clinics of North America, 43 (1) pp. 47-62. Peer-reviewed.
[DOI][Pmid][serval:BIB_A2BABDD19CB1]
 
Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study.
Mathieu R., Klatte T., Lucca I., Mbeutcha A., Seitz C., Karakiewicz P.I., Fajkovic H., Sun M., Lotan Y., Scherr D.S. et al., 2016. Bju International, 118 (2) pp. 243-249. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E34A8C3EC884]
2015
 
Gender differences in incidence and outcomes of urothelial and kidney cancer.
Lucca I., Klatte T., Fajkovic H., de Martino M., Shariat S.F., 2015/12..
[DOI][WoS][Pmid][serval:BIB_95472947DDB7]
 
Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer.
de Martino M., Lucca I., Mbeutcha A., Wiener H.G., Haitel A., Susani M., Shariat S.F., Klatte T., 2015/10. European urology, 68 (4) pp. 552-554. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2813A409D3E1]
 
Preoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma (RCC).
de Martino M., Leitner C.V., Seemann C., Hofbauer S.L., Lucca I., Haitel A., Shariat S.F., Klatte T., 2015/03. BJU international, 115 (3) pp. 397-404. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CD8AC8290ADE]
 
Adjuvant cisplatin-based combined chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of >1500 patients.
Lucca I., Rouprêt M., Kluth L., Rink M., Tilki D., Fajkovic H., Kassouf W., Hofbauer S.L., de Martino M., Karakiewicz P.I. et al., 2015. Bju International, 115 (5) pp. 722-727. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CD1E0840E9EA]
 
Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer.
de Martino M., Shariat S.F., Hofbauer S.L., Lucca I., Taus C., Wiener H.G., Haitel A., Susani M., Klatte T., 2015/01. World journal of urology, 33 (1) pp. 105-110. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_753C4BCA872D]
 
Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma.
Lucca I., de Martino M., Hofbauer S.L., Zamani N., Shariat S.F., Klatte T., 2015. World Journal of Urology, 33 (12) pp. 2045-2052. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_62D2B7FA1B22]
 
Diagnosis and Management of Upper Tract Urothelial Carcinoma.
Lucca I., Leow J.J., Shariat S.F., Chang S.L., 2015. Hematology/oncology Clinics of North America, 29 (2) pp. 271-288. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A6E7CF897D87]
 
Histopathology and prognosis of de novo bladder tumors following solid organ transplantation.
Ederer I.A., Lucca I., Hofbauer S.L., Haidinger M., Haitel A., Susani M., Shariat S.F., Klatte T., 2015. World Journal of Urology, 33 (12) pp. 2087-2093. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2C00A97F7D92]
 
Inégalité des sexes face au cancer en urologie [Gender disparities in urologic cancers].
Lucca I., Valerio M., Jichlinski P., Cerantola Y., 2015. Revue Médicale Suisse, 11 (497) pp. 2276-8, 2280.
[Pmid][serval:BIB_F61CE55212D3]
 
Kidney-sparing surgery for upper tract urothelial cancer.
Lucca I., Klatte T., Rouprêt M., Shariat S.F., 2015. Current Opinion in Urology, 25 (2) pp. 100-104. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FD37600480F3]
 
Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy.
Mathieu R., Shariat S.F., Seitz C., Karakiewicz P.I., Fajkovic H., Sun M., Lotan Y., Scherr D.S., Tewari A., Montorsi F. et al., 2015. World Journal of Urology, 33 (8) pp. 1165-1171. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_66B956D8A844]
 
Novel biomarkers to predict response and prognosis in localized bladder cancer.
Lucca I., de Martino M., Klatte T., Shariat S.F., 2015. Urologic Clinics of North America, 42 (2) pp. 225-33, ix. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3B4A681FC901]
 
Outcomes of minimally invasive simple prostatectomy for benign prostatic hyperplasia: a systematic review and meta-analysis.
Lucca I., Shariat S.F., Hofbauer S.L., Klatte T., 2015. World Journal of Urology, 33 (4) pp. 563-570. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A44D4E74F633]
 
The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma.
Hofbauer S.L., Pantuck A.J., de Martino M., Lucca I., Haitel A., Shariat S.F., Belldegrun A.S., Klatte T., 2015. Urologic Oncology, 33 (2) pp. 68.e1-68.e7. Peer-reviewed.
[DOI][Pmid][serval:BIB_3C92C45C7428]
 
The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study.
Lucca I., Kassouf W., Kapoor A., Fairey A., Rendon R.A., Izawa J.I., Black P.C., Fajkovic H., Seitz C., Remzi M. et al., 2015. BJU International, 116 (1) pp. 72-78. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2359E9AA3C78]
 
The T309G Murine Double Minute 2 Gene Polymorphism Is an Independent Prognostic Factor for Patients with Renal Cell Carcinoma.
de Martino M., Taus C., Wessely I.S., Lucca I., Hofbauer S.L., Haitel A., Shariat S.F., Klatte T., 2015. Dna and Cell Biology, 34 (2) pp. 107-112. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E55F7CC9B9AA]
 
Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy?
Mathieu R., Lucca I., Klatte T., Babjuk M., Shariat S.F., 2015. Current Opinion In Urology, 25 (5) pp. 476-482. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DCA46EB3142C]
Upper urinary tract disease: what we know today and unmet needs
Mathieu , Bensalah , Lucca , Mbeutcha , Rouprêt , Shariat , 2015. Translational Andrology and Urology, 4 (3) pp. 261-272. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_C09105C57C8D]
 
Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model.
Lucca I., Shariat S.F., Briganti A., Lotan Y., Roehrborn C.G., Montorsi F., Remzi M., Seitz C., Fajkovic H., Klingler C. et al., 2015. Urologic Oncology, 33 (2) pp. 71.e21-71.e26. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DCD023CAB4C6]
2014
Associations Between Presenting Symptoms, Clinicopathological Parameters, and Prognosis in a Contemporary Series of Patients With Renal Cell Carcinoma
Hofbauer S.L., de Martino M., Seemann C., Zamani N., Lucca I., Haitel A., Shariat S.F., Klatte T., 2014. Korean Journal of Urology, 55 (8) pp. 505-510. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_4E7C776F2378]
 
Comorbidity and nutritional indices as predictors of morbidity after transurethral procedures: A prospective cohort study.
Valerio M., Cerantola Y., Fritschi U., Hubner M., Iglesias K., Legris A.S., Lucca I., Vlamopoulos Y., Vaucher L., Jichlinski P., 2014. Canadian Urological Association Journal, 8 (9-10) pp. E600-E604. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FAAFB52000CA]
Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma.
Hofbauer S.L., Stangl K.I., de Martino M., Lucca I., Haitel A., Shariat S.F., Klatte T., 2014. British Journal of Cancer, 111 (8) pp. 1526-1531. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8F715C43D92F]
 
Sex steroids and gender differences in nonmuscle invasive bladder cancer.
Lucca I., Fajkovic H., Klatte T., 2014. Current Opinion In Urology, 24 (5) pp. 500-505. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3C4E930B9AA7]
 
Words of wisdom. Re: radical prostatectomy or watchful waiting in early prostate cancer.
Lucca I., Klatte T., Shariat S.F., 2014. European Urology, 66 (2) pp. 386-387. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_524E2A8079FD]
2013
 
The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Gontero P., Oderda M., Mehnert A., Gurioli A., Marson F., Lucca I., Rink M., Schmid M., Kluth L.A., Pappagallo G. et al., 2013/09. The Journal of urology, 190 (3) pp. 857-862. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B8755E77D49C]
2012
 
Troubles sexuels masculins et obésité [Male sexual dysfunction and obesity].
Lucca I., Paduch D.A., Pralong F., Vaucher L., 2012. Revue Médicale Suisse, 8 (365) pp. 2327-2330.
[Pmid][serval:BIB_2DAD861D088C]
2009
 
Fatal haematuria in a patient with an orthotopic neobladder and chronic liver failure.
Oderda M., Mondino P., Lucca I., Fiorito C., Gillo A., Zitella A., Greco A., Tizzani A., Gontero P., 2009. Urologia internationalis, 83 (3) pp. 368-369. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_13C79B015F89]
 
Iliac artery-ureteral fistula: a fatal hemorrhage in a man with ureterocutaneostomy.
Morelli B., Berta G., Cattaneo E., Lucca I., Fiorito C., Oderda M., Mondino P., Valentino F., 2009. Urologia, 76 (1) pp. 53-55. Peer-reviewed.
[Pmid][serval:BIB_E20FD4E0CFB4]
2008
 
New drugs currently available in non-muscle invasive bladder cancer: update on gemcitabine studies.
Gontero P., Fiorito C., Lucca I., Valentino F., Tizzani A., 2008/12. Archivio italiano di urologia, andrologia, 80 (4) pp. 162-166. Peer-reviewed.
[Pmid][serval:BIB_4F60BD48EEDB]
 
[Neuroendocrine bladder cancer: oncological emergency?].
Fiorito C., Lucca I., Oderda M., Mondino P., Berta G., Cattaneo E.A., Valentino F., Zitella A., Pacchioni D., 2008. Urologia, 75 (1) pp. 57-61. Peer-reviewed.
[Pmid][serval:BIB_E5AFCF1F4E04]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University